Brevan Howard Capital Management LP Cullinan Oncology, Inc. Transaction History
Brevan Howard Capital Management LP
- $9.23 Billion
- Q1 2025
A detailed history of Brevan Howard Capital Management LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 40,599 shares of CGEM stock, worth $318,296. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,599
Previous 14,735
175.53%
Holding current value
$318,296
Previous $179,000
71.51%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$60 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$45.1 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$30.3 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$27.8 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$26.8 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $358M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...